Philippe C. Bishop - 09 Jan 2023 Form 4 Insider Report for Atreca, Inc.

Reporting relationship: Chief Medical Officer
Issuer ticker: N/A
Reported as of: 09 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jan 2023, 17:44:13 UTC
Source filing: View source filing
Reporting owner signature: /s/ Courtney Phillips, attorney-in-fact

Key filing fact

Philippe C. Bishop filed Form 4 for Atreca, Inc. on 11 Jan 2023.

Key facts

This page summarizes Philippe C. Bishop's Form 4 filing for Atreca, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Jan 2023, 17:44.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCEL transaction Derivative

Employee stock option (right to buy)

Award

Transaction value: $0
Shares: +350,000
Change %
Price: $0.000000
Shares after: 350,000
Date: 09 Jan 2023
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 350,000
Exercise price: $1.37
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares of Class A common stock underlying the Option shall vest on January 9, 2024 and the remainder of the shares of Class A common stock underlying the Option shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.